[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100602476":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":21,"locations":27,"responsibleParty":180,"collaborators":10,"id":182,"slug":10,"hasResults":183,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":183,"sex":189,"minAge":190,"maxAge":191,"enrollmentInfo":192,"targetDuration":10,"studyType":195,"phases":10,"briefSummary":196,"conditions":197,"keywords":10,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":234},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Trastuzumab deruxtecan",null,"Patients with locally advanced, unresectable, or metastatic HER-2 positive (IHC3+) solid tumours for whom a clinician decision has been made for treatment with T-DXd as part of routine clinical practice and in line with the FDA label",[13],"Drug: Trastuzumab deruxtecan",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Trastuzumab deruxtecan monotherapy",[9],[20],"Enhertu",[22],{"name":23,"role":24,"phone":25,"phoneExt":10,"email":26},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[28,41,50,58,67,76,85,93,101,110,119,128,136,145,153,162,171],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":10},"Research Site","RECRUITING","Birmingham","Alabama","35243","United States",{"type":36,"coordinates":37},"Point",[38,39],-86.80249,33.52066,{"lat":39,"lon":38},{"facility":29,"status":30,"city":42,"state":43,"zip":44,"country":34,"cosmosGeoPoint":45,"geoPoint":49,"contacts":10},"Bullhead City","Arizona","86442",{"type":36,"coordinates":46},[47,48],-114.5683,35.14778,{"lat":48,"lon":47},{"facility":29,"status":30,"city":51,"state":43,"zip":52,"country":34,"cosmosGeoPoint":53,"geoPoint":57,"contacts":10},"Casa Grande","85122",{"type":36,"coordinates":54},[55,56],-111.75735,32.8795,{"lat":56,"lon":55},{"facility":29,"status":30,"city":59,"state":60,"zip":61,"country":34,"cosmosGeoPoint":62,"geoPoint":66,"contacts":10},"San Diego","California","92123",{"type":36,"coordinates":63},[64,65],-117.16472,32.71571,{"lat":65,"lon":64},{"facility":29,"status":30,"city":68,"state":69,"zip":70,"country":34,"cosmosGeoPoint":71,"geoPoint":75,"contacts":10},"Boulder","Colorado","80309",{"type":36,"coordinates":72},[73,74],-105.27055,40.01499,{"lat":74,"lon":73},{"facility":29,"status":30,"city":77,"state":78,"zip":79,"country":34,"cosmosGeoPoint":80,"geoPoint":84,"contacts":10},"Coral Springs","Florida","33065",{"type":36,"coordinates":81},[82,83],-80.2706,26.27119,{"lat":83,"lon":82},{"facility":29,"status":30,"city":86,"state":78,"zip":87,"country":34,"cosmosGeoPoint":88,"geoPoint":92,"contacts":10},"St. Petersburg","33714",{"type":36,"coordinates":89},[90,91],-82.67927,27.77086,{"lat":91,"lon":90},{"facility":29,"status":30,"city":94,"state":78,"zip":95,"country":34,"cosmosGeoPoint":96,"geoPoint":100,"contacts":10},"West Palm Beach","33401",{"type":36,"coordinates":97},[98,99],-80.05337,26.71534,{"lat":99,"lon":98},{"facility":29,"status":30,"city":102,"state":103,"zip":104,"country":34,"cosmosGeoPoint":105,"geoPoint":109,"contacts":10},"Decatur","Illinois","62526",{"type":36,"coordinates":106},[107,108],-88.9548,39.84031,{"lat":108,"lon":107},{"facility":29,"status":30,"city":111,"state":112,"zip":113,"country":34,"cosmosGeoPoint":114,"geoPoint":118,"contacts":10},"Topeka","Kansas","66604",{"type":36,"coordinates":115},[116,117],-95.67804,39.04833,{"lat":117,"lon":116},{"facility":29,"status":30,"city":120,"state":121,"zip":122,"country":34,"cosmosGeoPoint":123,"geoPoint":127,"contacts":10},"Durham","North Carolina","27708",{"type":36,"coordinates":124},[125,126],-78.89862,35.99403,{"lat":126,"lon":125},{"facility":29,"status":30,"city":129,"state":121,"zip":130,"country":34,"cosmosGeoPoint":131,"geoPoint":135,"contacts":10},"Wilson","27893",{"type":36,"coordinates":132},[133,134],-77.91554,35.72127,{"lat":134,"lon":133},{"facility":29,"status":30,"city":137,"state":138,"zip":139,"country":34,"cosmosGeoPoint":140,"geoPoint":144,"contacts":10},"Canton","Ohio","44718",{"type":36,"coordinates":141},[142,143],-81.37845,40.79895,{"lat":143,"lon":142},{"facility":29,"status":30,"city":146,"state":138,"zip":147,"country":34,"cosmosGeoPoint":148,"geoPoint":152,"contacts":10},"Maumee","43537",{"type":36,"coordinates":149},[150,151],-83.65382,41.56283,{"lat":151,"lon":150},{"facility":29,"status":30,"city":154,"state":155,"zip":156,"country":34,"cosmosGeoPoint":157,"geoPoint":161,"contacts":10},"Philadelphia","Pennsylvania","19104",{"type":36,"coordinates":158},[159,160],-75.16362,39.95238,{"lat":160,"lon":159},{"facility":29,"status":30,"city":163,"state":164,"zip":165,"country":34,"cosmosGeoPoint":166,"geoPoint":170,"contacts":10},"Nashville","Tennessee","37203",{"type":36,"coordinates":167},[168,169],-86.78444,36.16589,{"lat":169,"lon":168},{"facility":29,"status":30,"city":172,"state":173,"zip":174,"country":34,"cosmosGeoPoint":175,"geoPoint":179,"contacts":10},"Dallas","Texas","75390",{"type":36,"coordinates":176},[177,178],-96.80667,32.78306,{"lat":178,"lon":177},{"type":181,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100602476",false,"NCT07124000","DESTINY-PANTUMOUR04","Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study","DP-04","Inclusion Criteria:\n\n1. Adults aged ≥18 years\n2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options as determined by the Investigator (see Exclusion Criterion 1 for excluded solid tumors);\n3. A clinician decision has been made for treatment with T-DXd in accordance with the FDA label;\n4. HER2-positive (IHC 3+) by local testing prior to study enrolment at the time of signed and dated informed consent;\n5. Patients who are willing and able to provide a signed and dated informed consent.\n\nExclusion Criteria:\n\n1. Primary diagnosis of adenocarcinoma of the breast, adenocarcinoma of the colon or rectum, NSCLC, adenocarcinoma of the gastric body or gastroesophageal junction or hematological malignancies;\n2. Prior T-DXd therapy;\n3. Patients without a baseline assessment of tumor burden undertaken prior to initiating T-DXd.\n4. Patient is participating in a clinical trial at time of enrolment","ALL","18 Years","130 Years",{"count":193,"type":194},100,"ESTIMATED","OBSERVATIONAL","This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US",[198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224],"Adenocarcinoma (NOS)","Anal Cancer","Bladder Cancer","Cervical Cancer","Endometrial Cancer","Esophageal Cancer","Gall Bladder Cancer","Gastrointestinal Stromal Tumour","Head and Neck Cancer","Liver Cancer","Melanoma","Mouth Cancer","Nasopharangeal Cancer","Neuroendocrine, Gastrointestinal Cancer","Ovarian Cancer","Pancreatic Cancer","Prostate Cancer","Renal Cell Carcinoma","Salivary Gland Cancer","Sarcoma","Small Cell Lung Cancer","Testicular Cancer","Throat Cancer","Thyroid Cancer","Urethral Cancer","Vaginal Cancer","Vulvar Cancer","2026-06-26",{"date":227,"type":228},"2026-06-29","ACTUAL",{"date":230,"type":228},"2025-09-18",{"date":232,"type":194},"2028-03-30",{"name":5,"class":6},17]